Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A transient transfection system for identifying biosynthesized proteins processed and presented to class I MHC restricted T lymphocytes

Laurence C. Eisenlohr, Jonathan W. Yewdell and Jack R. Bennink

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Room 213, Building 4, Bethesda, MD 20892, USA

(Received 9 March 1992, revised received 23 April 1992, accepted 24 April 1992)

CD8+ cytotoxic T lymphocytes (CTL) constitute a major portion of immune responses to foreign and self antigens. CTL recognize class I major histocompatibility complex molecules complexed to peptides of 8–10 residues derived from cytosolic proteins. To understand CTL responses to these antigens and to manipulate CTL responses optimally, it is necessary to identify the specific peptides recognized by CTL. The methods currently used for this purpose have significant drawbacks. We describe a plasmid transfection method that results in significant lysis of histocompatible target cells. Influenza virus-specific CTLs specifically lysed target cells that were transfected with plasmids bearing cDNAs encoding full length gene products, fragments containing the region that encodes the CTL epitope, or even a ten residue peptide. This significantly lessens the time and effort required to define genes, and gene segments that contain CTL epitopes.

Key words: Cytotoxic T lymphocyte; Transfection; Vaccinia virus; Antigen presentation; T7 RNA polymerase

Introduction

CD8+ cytotoxic T lymphocytes (CTL) are a prominent part of many immune responses, and in certain circumstances have been shown to limit replication of intracellular parasites (viruses, unicellular eukaryotes or prokaryotes), or to have anti-tumor activities. They are also thought to be involved in autoimmune diseases. The central feature of CTL recognition is its major histocompatibility complex (MHC) restricted nature (Zinkernagel and Doherty, 1979). In recent years, there has been tremendous progress in understanding the molecular nature of CTL antigen recognition and how antigenic determinants are generated. CTL antigen receptors recognize peptides bound to the antigen binding groove of MHC class I molecules. In many cases these peptides consist of 8–10 residues (Rötzschke et al., 1990; Van Bleek and Nathenson, 1990), although it is likely that slightly longer peptides are...
also recognized. Peptides appear to be derived from a cytosolic pool of foreign or self proteins. In most circumstances, protein fragments are processed for presentation to CTL at least as efficiently as intact proteins (Tevethia et al., 1983; Townsend et al., 1985; Gould et al., 1989; Sweetser et al., 1989; Whitton and Oldstone, 1989).

In studying or manipulating CTL responses it is often useful, if not essential, to identify the precise peptide recognized by CTL specific for a given antigen. The first step in this process is to identify the protein from which the antigenic peptide is derived. It is possible at this stage to identify the antigenic peptide from a library of overlapping peptides, which bind directly to cell surface class I molecules and bypass the requirement for antigen processing. For most investigators, however, budgetary constraints severely limit this option, particularly if the protein is large. Thus, it is usually necessary to narrow down the location of the peptide in the protein by expressing fragments of the protein in the cell.

Expression of intact or fragmented proteins in the cytosol is usually achieved by genetic means, either through infection with recombinant DNA viruses, or selection of cell lines expressing the gene following DNA-mediated transfection. Both of these methods are labor intensive and time consuming. Much of the time is spent after the gene of interest has been inserted into a plasmid that is appropriate for eukaryotic expression or homologous recombination into a viral genome. In the present report we describe a method in which plasmid DNA can be used directly to transfect cells for use in a standard 51Cr release assay to monitor recognition by CTL. We show this method to be applicable for the expression of full-length gene products bearing a CTL determinant, fragments bearing the determinant, and even a ten residue peptide.

Materials and methods

Plasmids

The cDNA encoding the A/PR/8/34 influenza virus (PR8) nucleoprotein (NP) and PR8 hemagglutinin (HA) molecules in the pBR322 vector were kindly provided by Dr. Peter Palese, Mt. Sinai School of Medicine, New York. The HA gene was cloned into the HindIII restriction site, behind the T7 and CMV promoters, of the Re/CMV vector (Stratagene, La Jolla, CA). The NP gene was cloned into the EcoRI Site, behind the T7 promoter, of the pEB2X plasmid (kindly provided by Dr. Edward Berger, National Institute of Allergy and Infectious Diseases, Bethesda, MD) that has been previously described (Berger et al., 1988). The CMV-IL-2R plasmid, expressing the Tac subunit of the interleukin-2 receptor from the T7 and CMV promoters of the Re/CMV plasmid (Giordano et al., 1991) acted as a control and was provided by Dr. Bruce Howard (National Cancer Institute, Bethesda, MD). Gene fragments were created by polymerase chain reaction of the PR8 NP using synthetic oligonucleotide primers containing restriction endonuclease sites (SalI in the upstream primer and NotI in the downstream primer) to enable directional ligation, the ATG initiation codon preceded by the sequence CCACC for efficient translation (Kozak, 1989) in the upstream primer, and a double stop codon (TAGTGA) in the downstream primer. The non-annealing bases were flanked by 10 bases that fully annealed to the target DNA. PCR products were digested with SalI and NotI and inserted behind the vaccinia virus (Vac) early-late P7.5 promoter in a modified version of the pSC11 plasmid (Chakrabarti et al., 1985) in which the Smal site was replaced by SalI and NotI.

Viruses

Vac recombinants expressing the A/PR8/34 influenza (PR8) nucleoprotein (NP) and PR8 hemagglutinin (HA) genes and the T7 RNA polymerase have been described (Yewdell et al., 1985; Bennink et al., 1986; Fuerst et al., 1986). They were grown and titred in the thymidine kinase negative human osteosarcoma 143B cell line (ATCC, Rockville, MD) in Dulbecco's modified Eagle's medium (DMEM) with 7.5% fetal bovine serum (FBS) at 37°C in an air/CO2 (91%/9%) atmosphere.

Cell lines

L929 cells, serving as antigen presenting cells (APC) in the assays, were maintained in DMEM
with 7.5% FBS at 37°C in an air/CO\textsubscript{2} (91%/9%) atmosphere. The L-Kd-172 cell line was maintained similarly and was established by selecting L929 cells stably expressing the K\textsuperscript{d} class I MHC molecule on the cell surface following transfection with the pKCKdwt plasmid (kindly provided by Dr. Christian Jaulin, The Pasteur Institute, Paris), that contains the K\textsuperscript{d} cDNA under control of the SV40 early promoter.

**Virus infections**

APC were infected for 1 h at 37°C with Vac recombinants at 10 plaque forming units (pfu) per cell at a concentration of 10\textsuperscript{7} cells/ml in balanced salt solution with 0.1% BSA (BSS/BSA). Generally 2 x 10\textsuperscript{6} APC were used for each infection. Afterward, 10 ml of Iscove's modified Dulbecco's medium (IMDM) supplemented with 7.5% FBS were added and the L929 cells incubated an additional 3 h at 37°C with rotation.

**Transfections**

Subconfluent L929 or L-Kd-172 cells were either transfected adhered to a six-well plate or in suspension.

**Adherent cells.** For adherent cells, two wells for each transfection were used. Cells were washed once with BSS/BSA and each well was infected for 30 min with 2 x 10\textsuperscript{7} pfu of vTF7-3 Vac in 0.2 ml of BSS/BSA, with rocking of the plate after 15 min. During this time, a stock of Lipofectin (Gibco BRL, Bethesda, MD) was vigorously vortexed and 30 μl were added to 1 ml of Optimem (Gibco BRL). This was then added to 10 μg of plasmid in 1 ml of Optimem. The mixture was vortexed briefly and allowed to stand for 15 min. Virus was removed from the wells and 1 ml of the DNA/Lipofectin mixture was added to each well and the plate incubated for 4 h at 37°C in an air/CO\textsubscript{2} (91%/9%) atmosphere.

**Cells in suspension.** APC in suspension were transfected as follows: 2 x 10\textsuperscript{6} cells were washed once with BSS/BSA and infected for 30 min in a 15 ml conical polystyrene tube with 2 x 10\textsuperscript{7} pfu of VTF-7.3 0.2 ml BSS/BSA, with constant slow rotation at 37°C. Cells were pelleted and 1 ml of DNA/Lipofectin mixture, described above, was added to each tube. The cells in suspension were then incubated for 4 h with constant rotation at 37°C.

**Immunofluorescence**

Just before labeling of APC with \textsuperscript{51}Cr, a portion of cells from each infection or infection/transfection was transferred to a new tube and allowed to rotate until the \textsuperscript{51}Cr release assay had been completed. At that time these cells were washed twice with PBS, brought up in 0.3 ml of ice-cold DPBS and then 0.7 ml of ice-cold absolute ethanol was added slowly with gentle vortexing. These fixed and permeabilized cells were washed three times with DPBS and then incubated at 4°C with H28-E23 anti-HA (Gerhard et al., 1981) or HB 65 anti-NP (Yewdell et al., 1981) culture supernatants for 1 h. Cells were then washed three times with cold DPBS and incubated in identical fashion with a fluorescein-conjugated rabbit anti-mouse immunoglobulins preparation (DAKO, Carpinteria, CA) in DPBS with 2% BSA. After washing three times with DPBS, fluorescence was quantitated using an Epics cytofluorograph (Coulter, Hialeah, FL).

**CTL assays**

Adherent cells were trypsinized and all infected/transfected cells were pelleted, suspended at 5 x 10\textsuperscript{7} cells/ml in IMDM with 50–100 μCi of Na\textsubscript{2}\textsuperscript{51}CrO\textsubscript{4} (Amersham, Arlington Heights, IL) and incubated for 1 h at 37°C. APC were then washed three times with DPBS, suspended in IMDM and combined with CTL populations (described below) in round-bottom plates at 10\textsuperscript{4} APC/well. The final volume per well was 0.2 ml. APC and CTL were coincubated for 4 h at 37°C before supernatants were collected (0.1 ml volumes) and counted in a Packard 5010 Cobra gamma detector. The data are presented as percent specific \textsuperscript{51}Cr release, defined as follows:

\[
\frac{(\text{experimental cpm}) - (\text{spontaneous cpm})}{\text{total cpm} - \text{spontaneous cpm}} \times 100
\]

**Generation of CTL**

CTL populations were generated as described (Yewdell et al., 1985). Briefly, CBA (H-2\textsuperscript{k}) and BALB/c (H-2\textsuperscript{d}) mice (Jackson Laboratories, Bar
Harbor, Maine) were injected intravenously with 10^7 pfu of Vac recombinants in 0.5 ml of DPBS. After 2–8 weeks splenocytes were harvested. Roughly one-third of the total spleen cells were infected with PR8 or the non-recombinant CR-19 Vac, washed, and mixed with the remaining cells in IMDM. Cultures were harvested after 6 or 7 days incubation at 37°C and used in the CTL assays as described above. Animal care was in accordance with NIH guidelines.

Results

Transfection with full-length genes

Because the standard in vitro assay for CTL recognition is assessed by release of ^51^Cr from APC, it is critical that most APC express the target antigen. This requirement has limited the usefulness of transient transfections, which usually result in the expression of foreign genes in only a minority of the cells. For many cell types, however, efficiency of transfection can be enhanced significantly by first infecting with vaccinia virus (Vac) at high multiplicity of infection (Fuerst et al., 1986; Elroy-Stein et al., 1989; Elroy-Stein and Moss, 1990). Though the exact mechanism responsible for this effect is not understood, up to 100% of the transfected cells can be observed to express the protein of interest. To achieve high levels of expression in each transfectant, Fuerst et al. (1986) placed the gene of interest behind the T7 bacteriophage promoter, and utilized a Vac recombinant that expresses the T7 RNA polymerase in the cytosol early in the infectious cycle. Additionally, if a gene is placed behind a Vac promoter, then infection with non-recombinant Vac can be used to enhance transfection and drive expression of the gene (Cochran et al., 1985) albeit at lower levels than those obtained with the T7 system (Fuerst et al., 1986). We investigated the capacity of both systems to identify CTL target antigens.

L929 cells (H-2k) were infected with the T7 RNA polymerase-expressing vTF7-3 Vac and then transfected with plasmids bearing an influenza virus gene encoding either hemagglutinin (HA) or nucleoprotein (NP) behind the T7 promoter as described in the materials and methods section. A plasmid containing the gene encoding the Tac subunit of the interleukin-2 receptor (IL-2R) behind the T7 promoter served as an additional negative control. Infection and transfection were performed either with the L929 cells attached to plastic or in suspension following release by trypsinization. L929 cells in suspension

| APC sensitized with | Percentage of cells positive by immunofluorescence for | Percent specific ^51^Cr release of targets exposed to CTL Specific for ^a^: |
|---------------------|--------------------------------------------------------|---------------------------------------------------------------------|
|                     | HA | NP | HA | NP | VAC | HA | NP | VAC |
| **Adherent cells**  |     |    |    |    |     |    |    |     |
| HA plasmid          | 80 | 2  | 55 | 38 | 25  | 14 | 87 | 76  |
| NP plasmid          | 1  | 74 | 20 | 16 | 67  | 53 | 93 | 78  |
| IL-2R DNA           | 2  | 1  | 22 | 11 | 22  | 10 | 89 | 75  |
| **Cells in suspension** |     |    |    |    |     |    |    |     |
| HA plasmid          | 48 | 10 | 40 | 40 | 9   | 2  | 79 | 65  |
| NP plasmid          | 2  | 77 | 14 | 3  | 78  | 61 | 86 | 73  |
| IL-2R DNA           | 2  | 1  | 8  | 1  | 4   | 5  | 81 | 68  |
| HA-Vac              | 71 | 2  | 49 | 28 | 13  | 6  | 87 | 67  |
| NP-Vac              | 4  | 84 | 18 | 7  | 82  | 55 | 91 | 71  |
| Vac                 | 7  | 1  | 15 | 8  | 12  | 7  | 83 | 66  |

^a^ Values given are for CTL:APC ratios of 6.6:1 and 2.2:1.
were also infected with a non-recombinant Vac (WR), or Vac recombinants expressing HA or NP.

Following 4 h incubation, cells were labeled with $^{51}$Cr and tested for recognition by CTL specific for HA or NP derived from CBA mice (H-2$^d$). Immunofluorescence studies using HA- and NP-specific monoclonal antibodies showed that, in general, 70–80% of the cells contained detectable amounts of antigen regardless of whether it was encoded within the Vac genome or on the plasmid (Table I). Since T cells are capable of responding fully to antigen present in the cell at levels barely detectable by immunofluorescence (Tevethia et al., 1983; Townsend et al., 1984, 1985), this range is likely to be a low estimate of the percentage of APC recognizable by antigen-specific CTL. As summarized in Table I, transfection of cells with the appropriate genes sensitized L929 cells (H-2$^d$) for specific lysis by NP- or HA-specific CTL. Transfected cells were lysed at similar levels as non-transfected cells infected with Vac recombinants containing the same gene. Transfection of cells in suspension was slightly more effective than transfection of adherent cells and is somewhat more convenient to carry out. The specificity of recognition is demonstrated in two ways. First, cells transfected with IL-2R Tac gene are not recognized by influenza specific CTL. This is not due to poor infection with T7 Vac, since the cells were efficiently lysed by Vac-specific CTL. Nor is it due to lack of transfection since the cells express Tac as determined by cytofluorography (not shown).

| APC sensitized with: | Percent specific $^{51}$Cr release of targets exposed to CTL specific for |
|---------------------|--------------------------------------------------------------------------------|
|                     | HA | NP | VAC |
| 1-168 NP plasmid    | 5  | 33 | 32  | 71 | 64 |
| M147-315 NP plasmid | 11 | 39 | 41  | 66 | 57 |
| M296-496 NP plasmid | 5  | 0  | 4   | 73 | 60 |
| M147-155 NP plasmid | 7  | 55 | 54  | 66 | 59 |
| HA-Vac              | 64 | 5  | 77  | 62 |
| NP-Vac              | 8  | 63 | 76  | 69 |

*Values given are for CTL:APC ratios of 9:1 and 3:1.

Similar results were obtained in three additional assays. Thus, this method of transfection can be used to express intact protein antigens at levels sufficient to effect significant lysis by antigen-specific CTL.

**Transfection of gene fragments**

To explore the ability of the system to identify gene fragment products carrying a CTL determinant, and to examine the possibility of driving expression with a Vac promoter, four other constructs were tested. It has been shown that the CTL response to NP by H-2$^d$ haplotype-mice is restricted to the K$^d$ class I molecule and that amino acids 147–155 comprise the segment of NP bound to K$^d$ (Rötzschke et al., 1990). Using polymerase chain reaction methodology, the NP gene was divided into slightly overlapping thirds, encoding amino acid residues 1–168, 147–315, and 296–496. Initiation codons were introduced before the second and third segments, an. gene segments were each placed behind the vaccinia P$^S$ promoter of the pSC11 plasmid. This promoter has been shown to be significantly weaker than the T7 promoter in the Vac-transfection system (Fuerst et al., 1986). This is due in part to the fact that, although the P$^S$ is normally active during both early and late phases of infection, early gene expression is quite low under the conditions employed (Cochran et al., 1985). Since transcription of these genes was controlled by an authentic Vac promoter, it was possible to substitute wild type Vac for the vTF7–3 recombinant for infection of L929 cells expressing K$^d$. The first and second gene fragments both code for amino acids 1–168, and both could potentially sensitize cells for lysis by K$^d$-restricted, NP-specific CTL. Table II shows that cells transfected with plasmids containing either of these segments are lysed by NP- (but not HA-) specific CTLs, while cells transfected with a plasmid encoding the carboxy terminal third of NP are not lysed above background values. When expressed by a recombinant vaccinia virus, this fragment does stimulate lysis by H-2$^b$ CTL that recognize residues 366–374 of NP (Rötzschke et al., 1990) (data not shown).

We recently showed that a Vac recombinant encoding NP residues 147–155, preceded by a
methionine efficiently sensitizes cells for NP-specific CTL lysis and induced NP-specific CTL responses in vivo (Eisenlohr et al., 1992). A mini-gene encoding this peptide was also placed behind the Vac P<sub>7.5</sub> promoter in the pSC11 vector. K<sup>d</sup>-expressing L929 cells transfected with this plasmid following infection with wild type Vac were efficiently lysed by NP-specific CTL (Table II).

Discussion

The findings reported here demonstrate that the Vac transfection system can be used to test for the presence of CTL epitopes in gene fragments, and can even be used to express the actual epitope at levels sufficient to effect a high degree of antigen-specific lysis. Further, when employed in this transfection scheme, a Vac promoter is clearly potent enough to drive sufficient gene expression for detection in a standard CTL assay.

Given the extensive use of the Vac/T7 RNA polymerase hybrid expression system (for examples see: Zagouras and Rose, 1989; Chavrier et al., 1990; Rich et al., 1990; Gallagher et al., 1991), Vac transfection should be applicable to a wide variety of target cells, allowing analysis of CTL restricted to virtually any human or mouse class I allomorph. Not all cell lines will be susceptible to this technique. In our case, we were unable to effect antigen-specific lysis of P815 cells although they have been used extensively in CTL assays involving infection with Vac recombinants.

Our findings indicate that the Vac transfection system should enable rapid identification of a gene or gene segment containing peptides recognized by CTL. The precise location of the peptide within the gene can be accomplished relatively quickly and inexpensively by progressively fragmenting the epitope-bearing gene with PCR. After locating the determinant to gene segments encoding 50-100 residues, relatively small sets of overlapping peptides can be used to identify the precise class I-binding peptide. For peptides that bind to class I allomorphs for which specific peptide motifs have been identified, it will often be possible to identify the precise peptide from quite large segments (Pamer et al., 1991; Rötzschke et al., 1991).

A shortcoming of the system as it stands is the difficulty in interpreting a negative result, since short peptides are very difficult to detect biochemically and lack of recognition might be due to poor transfection. This can be remedied by inserting in the plasmid a second gene or gene fragment that encodes a known target of CTL activity in the MHC or HLA type being investigated or that can be detected by immunofluorescence as shown above. The pSC11 plasmid, used in our experiments to drive antigen expression from a Vac promoter, does contain the gene for β-galactosidase behind the Vac P<sub>11</sub> late promoter and this could be exploited. Alternatively, one could effect a fusion of a detectable protein and the fragment in question, obviating the need for an additional promoter, but it must be kept in mind that sequences directly flanking a CTL epitope can negatively affect its recognition (Del Val et al., 1991; Eisenlohr et al., 1992). If one is to drive expression of a control gene with a separate Vac promoter, the relatively poor expression of genes behind early promoters in this system (Cochran et al., 1985) suggests that a late or early-late promoter should be employed.

The identification of cellular antigens recognized by CTL specific for tumor cells, allo antigens or minor histocompatibility antigens is a particularly challenging problem. In a limited number of situations this has been achieved by transfecting cells with pools of cosmids derived from cells expressing the target antigens, and screening transfected colonies for their ability to trigger T cell recognition (Van der Bruggen et al., 1991). The Vac transfection system could prove to be more sensitive and rapid than the currently used system. Although additional work would be necessary in designing vectors that optimize the chances of expressing antigenic determinants from cDNA libraries controlled by the T7 promoter, there would seem to be no insurmountable technical hurdles.

Acknowledgments

The authors would like to thank Judith L. Stephens and Christopher L. Allen for technical
assistance and Dr. Bernard Moss for suggesting the use of the infection/transfection system.

References

Bennink, J.R., Yewdell, J.W., Smith, G.L. and Moss, B. (1986) Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J. Virol. 57, 786.

Berger, E.A., Fuerst, T.R. and Moss, B. (1988) A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 85, 2357.

Chakrabarti, S., Brechling, K. and Moss, B. (1985) Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5, 3403.

Chavrier, P., Parton, R.G., Hauri, H.P., Simons, K. and Zerial, M. (1990) Localization of low molecular weight GTP binding proteins to exocytic and endocytic compartments. Cell 62, 317.

Cochran, M.S., Mackett, M. and Moss, B. (1985) Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus. Proc. Natl. Acad. Sci. USA 82, 19.

Del Val, M., Schlicht, H.-J., Ruppert, T., Reddehase, M.J. and Koszinowski, U.H. (1991) Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66, 1145.

Eisenlohr, L.C., Yewdell, J.W. and Bennink, J.R. (1992) Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J. Exp. Med. 175, 481.

Elroy-Stein, O. and Moss, B. (1990) Cytoplasmic expression system based on constitutive synthesis of bacteriophage T7 RNA polymerase in mammalian cells. Proc. Natl. Acad. Sci. USA 87, 6743.

Elroy-Stein, O., Fuerst, T.R. and Moss, B. (1989) Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5′ sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc. Natl. Acad. Sci. USA 86, 6126.

Fuerst, T.R., Niles, E.G., Studier, F.W. and Moss, B. (1986) Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. USA 83, 8122.

Gallagher, T.M., Escarmis, C. and Buchmeier, M.J. (1991) Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein. J. Virol. 65, 1916.

Gerhard, W., Yewdell, J.W., Frankel, M.E. and Webster, R.G. (1981) Antigenic structure of influenza virus hemagglutinin defined by hybridoma antibodies. Nature 290, 713.

Giordano, T., Howard, T.H., Coleman, J., Sakamoto, K. and Howard, B.H. (1991) Isolation of a population of transiently transfected quiescent and senescent cells by magnetic affinity cell sorting. Exp. Cell Res. 192, 193.

Gould, K., Cossins, J., Bastin, J., Brownlee, G.G. and Townsend, A. (1989) A 15 amino acid fragment of influenza nucleoprotein synthesized in the cytoplasm is presented to class I-restricted cytotoxic T lymphocytes. J. Exp. Med. 170, 1051.

Kozak, M. (1989) The scanning model for translation: an update. J. Cell Biol. 108, 229.

Pamer, E.G., Harty, J.T. and Bevan, M.J. (1991) Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature 353, 852.

Rich, D.P., Anderson, M.P., Gregory, R.J., Cheng, S.H., Paul, S., Jefferson, D.M., McCann, J.D., Klinger, K.W., Smith, A.E. and Welsh, M.J. (1990) Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 347, 358.

Rötzschke, O., Falk, K., Deres, K., Schild, H., Norda, M., Metzger, J., Jung, G. and Rammensee, H.-G. (1990) Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348, 252.

Rötzschke, O., Falk, K., Stevanovic, S., Jung, G., Walden, P. and Rammensee, H.-G. (1991) Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21, 2891.

Sweetser, M.T., Morrison, L., Braciale, V.L. and Braciale, T.J. (1989) Recognition of pre-processed endogenous antigen by class I but not class II MHC-restricted T cells. Nature 342, 180.

Tevethia, S., Tevethia, M., Lewis, A., Reddy, V. and Weissman, S. (1983) Biology of simian virus 40 (SV40) transplanted antigen (TrAg). IX. Analysis of TrAg in mouse cells synthesizing truncated SV40 large T antigen. Virology 128, 319.

Townsend, A.R.M., McMichael, A.J., Carter, N.P., Heddleston, J.A. and Brownlee, G.G. (1984) Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell 39, 13.

Townsend, A.R.M., Gotch, F.M. and Davey, J. (1985) Cytotoxic T cell recognizes fragments of the influenza nucleoprotein. Cell 42, 457.

Van Bleek, G.M. and Nathenson, S.G. (1990) Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kd molecule. Nature 348, 213.

Van der Bruggen, P., Traversari, C., Chromoz, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A. and Boon, T. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643.

Whitton, J.L. and Oldstone, M.B.A. (1989) Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes. J. Exp. Med. 170, 1033.

Yewdell, J.W., Frank, E. and Gerhard, W. (1981) Expression of influenza A virus internal antigens on the surface of infected P815 cells. J. Immunol. 126, 1814.

Yewdell, J.W., Bennink, J.R., Smith, G.L. and Moss, B. (1985) Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 82, 1785.
Zagouras, P. and Rose, J.K. (1989) Carboxy-terminal SEKDEL sequences retard but do not retain two secretory proteins in the endoplasmic reticulum. J. Cell Biol. 109, 2633.
Zinkernagel, R.M. and Doherty, P.C. (1979) MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 27, 52.